Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Period	PE Ratio
2021-12-31	-23.83
2022-12-31	-31.53
2023-12-31	-41.46
2024-12-31	-47.01

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TERN	$52.66	+0.07%	12.08M
3
4
5

Terns Pharmaceuticals Inc. (TERN) PE Ratio

PE Ratio Data

Get Terns Pharmaceuticals Inc. Data in Excel

More TERN Financial Data